Abstract
Angioplasty with or without stenting remains the mainstay of interventional therapy for arterial occlusive disease of the aortoiliac and femoropopliteal systems. Mortality in patients with peripheral arterial disease, however, derives primarily from systemic cardiovascular events. As such, all patients should have aggressive control of relevant risk factors (e.g., hypertension, diabetes, hyperlipidemia). Decisions regarding revascularization for patients with claudication must be individualized in contrast to patients with critical limb ischemia, who should routinely undergo revascularization. Noncomplex lesions of the iliac arteries may be treated with angioplasty alone; stenting should be reserved for special cases. Stent placement should be more liberal in complex aortoiliac lesions. Stent placement for femoropopliteal disease is more controversial. Techniques for conventional and subintimal angioplasty of both aortoiliac and femoropopliteal segments along with stent placement are described along with outcomes and postprocedural care.
Keywords
- Iliac Artery
- Peripheral Arterial Disease
- Critical Limb Ischemia
- Common Femoral Artery
- Interventional Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technique and a preliminary report of its application. Circulation. 1964;30:654–670.
Gruntzig A, Kumpe DA. Technique of percutaneous transluminal angioplasty with the Gruntzig balloon catheter. AJR 1979;132:547–552.
Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701–706.
Palmaz JC, Sibbitt RR, Reuter SR, Tio FO, Rice WJ. Expandable intraluminal graft: a preliminary study: work in progress. Radiology. 1985;156:73–77.
Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76:450–457.
Taute BM, Thommes S, Taute R, Rapmund I, Lindner K, Podhaisky H. Long-term outcome of patients with mild intermittent claudication under secondary prevention. Vasa. 2009; 38(5):346–355.
Aquino R, Johnnides C, Makaroun M, et al. Natural history of claudication: Long-term serial follow-up study of 1244 claudicants. J Vasc Surg. 2001; 34:962–970.
Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc. 2010;85(7):678–692.
Kannel WB, Shurtleff D. The Framingham Study: cigarettes and the development of intermittent claudication. Geriatrics. 1973;28(2):61–68.
Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253–260.
Kumakura G, Kanai H, Aizaki M, et al. The influence of the obesity paradox and chronic kidney disease on long-term survival in a Japanese cohort with peripheral arterial disease. J Vasc Surg. 2010;52(1):110–117.
Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925–1932.
Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975–980.
Regensteiner JG, Gardner A, Hiatt WR. Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status in 1997. Vasc Med. 1997;2:147–155.
Izquierdo-Porrera AM, Gardner AW, Powell CC, Katzel LI. Effects of exercise rehabailitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. J Vasc Surg. 2000;31:670–677.
Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–1919.
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339.
Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Gramingham Heart Study. Circulation. 1997;96:44–49.
Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Study. J Am Geriatr Soc. 1985;33:13–18.
Kannel WB, McGee D. Diabetes and cardiovascular disease. The Framingham Study. JAMA. 1979;241:2035–2038.
Kannel WB, D’Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience. Am Heart J. 1990;120:672–676.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
Sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-VI). Arch Intern Med. 1997;157:2413–2446.
Vogt MT, Cauley JA, Kuller LH, Hulley SB. Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol. 1993;137:559–568.
Safar ME, Laurent S, Asmar RE, et al. Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. Angiology. 1987;38:287–295.
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ADD/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease(lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular Pulmonary Rehabilitation: National Heart, Lung, and Blood Institute; Society for Vascular ; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654.
Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769–1776.
Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis : the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103(7):919-925.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; Heart Outcomes Prevention Evaluation Study Investgators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145–153.
Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;262(9386):782–788.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):7–22.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
Olsson AG, Ruhn G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. J Intern Med. 1990;227:381–390.
McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107(5):757–761.
Giri J, McDermott MM, Greenland P, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol. 2006;47(5):998–1004.
Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2000; (2):CD000990.
Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J. 1996;155:1053–1059.
Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;150:337–345.
Regensteiner JG, Hiatt WR. Improvements in quality of life in cilostazol-treated patients with intermittent claudication. Vasc Med. 2000;5:198.
Beebe HG, Dawson GL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;150:2041–2049.
Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998;27:267–274.
Strandness DE Jr. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized multicenter trial. Circulation. 1998;95:I–12.
Dawson D, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523–530.
Whyman MR, Ruckley CV. Should claudicants receive angioplasty or just exercise training? Cardiovascular Surgery. 1998;6(3):226–231.
Spronk S, Bosch JL, Veen HF, den Hoed PT, Hunink MGM. Intermittent claudication: functional capacity and quality of life after exercise training or percutaneous transluminal angioplasty—systematic review. Radiology. 2005;235:833–842.
Wilson S, Gelfand D, Jimenez J, Gordon I. Comparison of the results of percutaneous transluminal angioplasty and stenting with medical treatment for claudicants who have superficial femoral artery occlusive disease. Vascular. 2006;14(2):81–87.
Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo Ballon Angioplasty versus Conservative Treatment Study (OBACT)—The 2-years results of a single centre, prospective, randomized study in patients with intermittent claudication. Eur J Vasc Endovas Surg. 2007;33:3–12.
The MIMIC Trial Participants. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from tow randomized trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovas Surg. 2008;36:680–688.
Mazari JAK, Gulati S, Rahman MNA, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg. 2010;24:69–79.
Management of peripheral arterial disease(PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31:S1–S206.
Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Current Drug Targets. Cardiovascular & Haematological Disorders. 2004;4:219–225.
Slovut DP, Sullivan TM. Critical limb ischemia: medical and surgical management. Vascular Med. 2008;13:281–291.
Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia J Vasc Surg. 2010;51:230–241.
Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomized controlled trial. Lancet. 2005;366:1925–1934.
Walsh JJ Jr, Cofelice M, Limpkin D, Kerstein MD. Is screening for vascular disease a valuable proposition? J Cardiovasc Surg 1988;29:306–309.
U.S. Preventive Services Task Force. Screening for Peripheral Arterial Disease: Recommendation Statement. AHRQ Publication No. 05-0583-A-EF. Rockville, MD: Agency for Healthcare Research and Quality. 2005. http://www.ahrq.gov/clinic/uspstf05/pad/padrs.htm
Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324.
Hirsch AT, Halverson SL, Treat-Jacobson D, et al. The Minnesota regional peripheral arterial disease screening program: toward a definition of community standards of care. Vascular Med. 201;6:87–96.
Bolia A, Fishwick G. Recanalization of iliac artery occlusions by subintimal dissection using the ipsilateral and the contralateral approach. Clin Radiol. 1997;52(9):684–687.
Leville CD, Kashyap VS, Clair DG, et al. Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients. J Vasc Surg. 2006;43:32–39.
Gandini R, Gabiano S, Chiocchi M, Chiappa R, Simonetti G. Percutaneous treatment in iliac artery occlusion: long-term results. Cardiovasc Intervent Radiol. 2008;31:1069–1076.
Motarjeme A, Gordon GI, Bodenhagen K. Thrombolysis and angioplasty of chronic iliac artery occlusions. JVIR. 1995; 6:66S–72S.
Taddei G, Tamellini P, Niccolo F, Antonio I. Thrombolysis during the endovascular treatment of iliac artery occlusions. Diagn Interv Radiol. 2010;16:84–89.
Klein W, van der Graaf Y, Seeger J, et al. Dutch iliac stent trial; long-term results in patients randomized for primary or selective stent placement. Radiology. 2005;238 (2): 734–744.
AbuRahma AF, Hayes JD, Flaherty SK, Peery W. Primary iliac stenting versus transluminal angioplasty with selective stenting. J Vasc Surg. 2007;46(5):965–970.
Krajcer Z, Sioco G, Reynolds T. Comparison of Wallfraft and Wallstent for treatment of complex iliac artery stenosis and occlusion. Tex Heart Inst J. 1997;24(3):193–199.
Rzucidlo EM, Powell RJ, Zwolak RM, et al. Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. J Vasc Surg. 2003;37:1175–1180.
Reekers JA, Bolia A. Percutaneous intentional extraluminal (subintimal) recanalization: how to do it yourself. Eur J Radiol. 1998;28:192–198.
Schillinger M, Sabeti S, Loewe C, et al. Galloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;254(18):1879–1888.
Laird JR, Katzen BT, Scheinert D, et al. RESILIENT investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.
Park KB, Do YS, Kim DI, et al. The TransAtlantic InterSociety Consensus (TASC) classification system in iliac arterial stent placement: long-term patency and clinical limitations. J Vasc Interv Radiol. 2007;18:193–201
Galaria II, Davies MG. Percutaneous transluminal revascularization for iliac occlusive disease: long-term outcomes in TransAtlantic Inter-Society Consensus A and B lesions. Ann Vasc Surg. 2005;19:352–360
Powell RJ, Fillinger M, Bettmann M, et al. The durability of endovascular treatment of multisegment iliac occlusive disease. J Vasc Surg. 2000;31:1178–1184
Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;351:1153–1159
Conrad MF, Cambria RP, Stone DH, et al. Intermediate results of percutaneous endovascular therapy of femoropopliteal occlusive disease: a contemporary series. J Vasc Surg. 2006;44:762–769
Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009;50:542–547.
Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–292.
Gonzalo B, Solanich T, Bellmunt S, et al. Cryoplasty as endovascular treatment in the femoropopliteal region: hemodynamic results and follow-up at one year. Ann Vasc Surg. 2010;24:680–685.
Laird J, Jaff MR, Biamino G, et al. Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol. 2005;16:1067–1073.
McKinsey JF, Goldstein L, Khan HU, et al. Novel treatment of patients with lower extremity ischemia: use of percutaneous atherectomy in 579 lesions. Ann Surg. 2008;248:519–528.
Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573–1578.
Laird JR, Zeller T, Gray BH, et al. LACI Investigators. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006;13:1–11
Wissgott C, Scheinert D, Rademaker J, Werk M, Schedel H, Steinkamp HJ. Treatment of long superficial femoral artery occlusions with excimer laser angioplasty: long-term results after 48 months. Acta Radiol. 2004;45:23–29.
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45:S5–S67.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Shah, S.K., Clair, D.G. (2012). Lower Extremity Intervention. In: Bhatt, D. (eds) Peripheral and Cerebrovascular Intervention. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60327-965-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-60327-965-9_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-964-2
Online ISBN: 978-1-60327-965-9
eBook Packages: MedicineMedicine (R0)